Steffen Brand

Steffen Brand is an accomplished Investment Director at ARCHIMED since February 2021, focusing on the Pharma Services Investment Team. In addition to this role, Steffen serves as a Board Member for Symbio Proinnovera and Cube Biotech GmbH, both backed by ARCHIMED, with the former specializing in dermatology-focused CRO services and the latter in membrane protein technologies. Steffen also holds a Board Observer position at SUANFARMA, a manufacturer of pharmaceutical ingredients, and previously at Direct Healthcare Group and FYTEXIA, contributing insights in medical devices and nutraceuticals, respectively. Steffen's earlier experience includes significant roles in corporate finance at FalkenSteg and Saxenhammer & Co., complemented by an MBA from HEC Paris and London Business School, focusing on Private Equity and Finance.